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Purpose: The phase III 22071–26071 trial was designed to evaluate the addition of panitumumab to adjuvant
chemotherapy plus intensity modulated radiotherapy (IMRT) in locally advanced resected squamous cell head and
neck cancer. We report the results of the dummy run (DR) performed to detect deviations from protocol guidelines.
Methods and Materials: DR datasets consisting of target volumes, organs at risk (OAR) and treatment plans were
digitally uploaded, then compared with reference contours and protocol guidelines by six central reviewers. Summary
statistics and analyses of potential correlations between delineations and plan characteristics were performed.
Results: Of 23 datasets, 20 (87.0%) GTVs were evaluated as acceptable/borderline, along with 13 (56.5%) CTVs and 10
(43.5%) PTVs. All PTV dose requirements were met by 73.9% of cases. Dose constraints were met for 65.2-100% of
mandatory OARs. Statistically significant correlations were observed between the subjective acceptability of contours
and the ability to meet dose constraints for all OARs (p≤ 0.01) except for the parotids and spinal cord. Ipsilateral
parotid doses correlated significantly with CTV and PTV volumes (p≤ 0.05).
Conclusions: The observed wide variations in treatment planning, despite strict guidelines, confirms the complexity of
development and quality assurance of IMRT-based multicentre studies for head and neck cancer.
Keywords: Head and neck, IMRT, Dummy run, EORTC ROGBackground
The management of locally advanced head and neck
squamous cell carcinoma (HNSCC) involves increasingly
complex combined modality approaches. After primary
surgery, conventionally-fractionated adjuvant radiother-
apy (RT), commonly delivered to a total dose of 64-66 Gy,
reduces the locoregional recurrence rate by at least half,
which has translated into a survival benefit [1-8]. The
addition of concurrent cisplatin has been investigated in
two major randomized trials with significant improve-
ments in progression-free [6,7] and overall survival (OS)
[6] overall, and for the subgroup of patients with extra-
capsular extension (ECE) and/or surgical margins <5 mm
[9]. Additionallly, blockade of the epidermal growth factor
receptor (EGFR) with cetuximab reduces the likelihood
of disease progression and increases 3-year OS by 10%* Correspondence: alysa@ualberta.ca
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unless otherwise stated.without enhancing typical RT side effects [10]. The
open-label, multicentre randomized phase III EORTC
22071 trial was designed to determine whether adding the
EGFR inhibitor panitumumab to adjuvant chemoradio-
therapy (CRT) concurrently would significantly prolong
disease-free survival (DFS) in macroscopically completely
resected HNSCC (ClinicalTrials.gov NCT01142414). Eli-
gible patients had surgically resected non-metastatic squa-
mous cell carcinoma of the hypopharynx, oropharynx,
larynx or oral cavity, stage pT1-2 node positive, or
any pT3-4 (UICC 6th Edition) at high risk of locore-
gional recurrence based on one or more of the following:
R0 resection with surgical margins <5 mm, R1 resection
(margin <1 mm) or ECE.
Variations in compliance with protocol RT delivery in
multicentre studies decrease tumour control, increase RT
toxicity and may negatively impact survival [11-19]. An
extensive quality assurance (QA) program increases inter-
institutional consistency and familiarizes participating sites
with EORTC procedures [16]. Centres undergoing pre-l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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protocol requirements [17], since QA ensures participating
institutions can adhere to protocol instructions, including
adequate contouring of volumes [18]. In a secondary ana-
lysis of available Radiation Oncology Group dummy run
(DR) cases over two decades, institutions which previously
completed a DR were significantly more likely to be suc-
cessful at other trials’ QA [19].
Planned RT QA procedures for EORTC 22071 in-
cluded completion of a trial-specific DR as well as a
complex dosimetry check (phantom irradiation). How-
ever, in spring 2011, the RTOG reported that adding con-
current cetuximab to CRT did not benefit patients with
locally advanced unresected HNSCC [20]. Therefore, test-
ing the same concept in the adjuvant setting with a differ-
ent investigational agent was not considered likely to be
beneficial. As a consequence, the trial was suspended in
July 2011 prior to accrual of its first patient. Despite clos-
ure of the trial, we analyzed completed DR datasets to as-
sess compliance with protocol guidelines.
Methods
DR procedure
The DR case history (Online Additional file 1) reflected
a 51 year old female with a pT2N1M0 left lateral tongue
HNSCC post-R1 resection (Figure 1). CT simulation im-
aging and preoperative CT and MRI scans were down-
loaded from the EORTC by participating institutions
and loaded into the local treatment planning systems
(TPS). Target volumes and organs at risk (OAR) were to
be defined and a protocol-compliant treatment plan gen-
erated. Subsequently, the planning CT in DICOM for-
mat, plus the structure set, 3D dose matrix and RT plan
(DICOM-RT format) were uploaded to the EORTC
Quality Assurance in Radiotherapy office via a web-
based tool. After evaluation for data integrity, datasets
were transmitted to the Image-Guided Therapy Quality
Assurance Centre (http://atc.wustl.edu) for review by the
trial QA team in relation to the master contours. Master
contours had been constructed independently by four
expert head and neck radiation oncologists according to
protocol guidelines (WB, JL, SN, CS), after which two
meetings were held to reach consensus.
Radiotherapy
The protocol recommended that the diagnostic CT be
co-registered with the postoperative planning CT to fa-
cilitate definition of the preoperative extent of primary
tumour (“GTV-pt”). A low risk volume (CTV52.8 Gy),
and areas at intermediate (CTV59.4 Gy) and high risk
(CTV66 Gy) of harbouring microscopic disease were to
be defined (Table 1). Volume selection guidelines were
outlined in the protocol, based on Gregoire et al. [21].
Although sites were given the option to encompass theentire LN level containing the LN with ECE for trial pa-
tients, for the DR patient, the preoperative extent of the
LN with ECE was considered to be clearly identifiable.
Therefore, only the reconstructed LN with ECE should
have been included. For all CTVs, 3D margin expansion
was to be anatomically adapted to avoid structures not
at risk for microscopic disease (eg air cavity, bone).
Three PTVs were to be generated using a recommended
margin of 5 mm; 3 mm was allowed if using advanced
position verification procedures. Required optimization
structures called ‘PTV-Exacts’ were equivalent to the re-
spective PTVs collapsed inside the external body con-
tour by 5 mm to avoid extension into the build-up
region. A simultaneous integrated boost (SIB) technique
with 6-10MV photons was required for all patients re-
ceiving intensity modulated RT (IMRT). Prescription
dose to the PTV1-Exact was 52.8 Gy (referred to
throughout as “PTV52.8 Gy-Exact”), PTV2-Exact was
59.4 Gy (“PTV59.4 Gy-Exact”), and PTV3-Exact was
66.0 Gy (“PTV66 Gy-Exact”), each delivered in 33 frac-
tions; at least 95% of the prescribed dose was to cover
95% of the PTV-Exacts.
Organs at risk
Delineation of the brainstem, spinal cord (equal to the os-
seous borders of vertebral canal), and parotid glands was
mandatory. All other OARs were considered optional.
Formal planning volume at risk margins were not utilized.
Central review
Four radiation oncologists and two medical physicists
participated in the central review procedure. Reviewers
evaluated volume selection and delineation in relation to
master contours (Figure 1), as well as treatment plan-
ning parameters, OAR dosimetry, dose distributions and
dose-volume histograms (DVH). Deviations were graded
as acceptable, borderline, and unacceptable based on the
defintions in Table 1 and taking into account all avail-
able information along with ICRU recommendations
[22]. For example, the final grade of the CTVs consid-
ered the degree of compliance of the GTV. In case of
discrepant judgments of reviewers, the grade was
assigned either by WB or by JL. Based on all reviewer
comments, an overall grade was given to each DR data-
set by WB or JL.
Statistical analysis
Descriptive statistics were compiled as proportions for
categorical variables, and averages (standard deviations)
for normally distributed continuous variables. Recalcu-
lated DVHs were used to assess dosimetric parameters.
Fisher’s exact test evaluated the correlation between two
categorical variables with cell count <5. The Spearman





Figure 1 Dummy run case imaging. Representative preoperative
(A) computed tomography and (B) axial T2-weighted magnetic
resonance image provided. (C) Axial, (D) coronal and (E) sagittal
display of master contours. Orange: GTV-pt. Magenta: CTV52.8 Gy.
Pink: CTV59.4 Gy. Red: CTV66 Gy. Blue: PTV52.8 Gy-Exact*. Green:
PTV2Exact*. Purple: PTV3Exact*. *PTVExacts denote PTVs collapsed
inside the skin by 5 mm.
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independent t-test compared OAR doses delivered to
volumes which did versus did not meet protocol con-
straints. A p value of ≤0.05 was considered statistically
significant. All analysis was conducted using IBM SPSS
version 19. The mean virtual radius was obtained for all
CTVs by calculating the radius of a sphere with the
identical volume as the corresponding CTV.
Results
Twenty-three DR cases were submitted from investiga-
tors in nine countries (10/2010-11/2011). All were IMRT
plans using dynamic multileaf collimation (34.8%), hel-
ical tomotherapy (21.7%), static multileaf collimation
(17.5%), volumetric modulated arc therapy (13.0%) or
technique not specified (13.0%). TPS included Eclipse
(52.5%), Tomotherapy HiART (17.4%), Pinnacle (8.7%),
Xio (8.7%), Monaco (4.3%), and not specified (8.8%).
Eleven (47.8%) sites successfully completed the phantom
irradiation for IMRT credentialing prior to submission of
the DR case. A median of 28 contours were submitted
per DR dataset (range 15–47) including optional plan-
ning optimization structures.
Volume delineation
GTV-pt contours were evaluated as acceptable in 9/23
(39.1%) cases, borderline in 11 (47.8%) and unacceptable
in three (13.0%). The specific LN with ECE was not recon-
structed by 10/23 sites, but this was not by itself sufficient
to downgrade the GTV if it was otherwise considered ac-
ceptable. Examples of submitted datasets with contours
graded overall as minor or major deviation are shown in
Figures 2 and 3 respectively. Volumetric indices of the
CTVs are shown in Figures 4A-C as well as the online
Additional file 1. Altogether, CTVs were termed accept-
able in 4/23 (17.4%) datasets, borderline in 9 (39.1%) and
unacceptable in 10 (43.5%). Contradicting protocol guide-
lines, 14/23 (60.9%) sites had at least one CTV crossing
anatomic boundaries, 5/23 (21.7%) included all or part of
level IA (ipsilateral or contralateral), 3/23 (13.0%) included
the ipsilateral level V LN, 3/23 (13.0%) did not encompass
all of the preoperative GTV, and 3/23 (13.0%) included the
entire post-surgical bed. CTV contour grade was not pre-
dicted by GTV contour grade (p = 0.23). PTVs were con-
sidered acceptable in 4/23 cases (17.4%), borderline in 6
(26.1%) and unacceptable in 13 (56.5%) (Figures 2, 3, 4
Table 1 Target volumes and normal tissues: objectives and constraints
Protocol compliant Minor deviation Major deviation
Target structure
CTV52.8 Gy • Bilateral neck irradiation to include levels IB, II, III and IV • Level IA or V included • Unilateral irradiation
• Complete levels IB, II, III or IV not included• Preoperative extent of primary tumour +15 mm
• Preoperative extent of tumour or LN with
ECE outside of CTV
• Reconstructed LN with ECE +10 mm
CTV59.4 Gy • Preoperative extent of primary tumour +10 mm – • Preoperative extent of tumour or LN with
ECE outside of CTV
• Reconstructed LN with ECE +10 mm
CTV66 Gy • Preoperative extent of primary tumour +10 mm – • Preoperative extent of tumour or LN with
ECE outside of CTV
• Reconstructed LN with ECE +5 mm
Volume objective Dose
PTV52.8 Gy-Exact D98% ≥47.52 Gy 46.57-47.52 Gy <46.57 Gy
D95% ≥50.16 Gy 49.16-50.16 Gy <49.16 Gy
PTV59.4 Gy-Exact D98% ≥53.46 Gy 52.93-53.46 Gy <52.93 Gy
D95% ≥56.43 Gy 55.30-56.43 Gy <55.30 Gy
PTV66 Gy-Exact D98% ≥59.4 Gy 58.21-59.40 Gy <58.21 Gy
D95% ≥62.7 Gy 61.45-62.70 Gy <61.45 Gy
D5% ≤72.6 Gy – >72.6 Gy
Normal tissue Dose constraint
Outside of PTV3* Max dose 72.6 Gy to a volume >1.8 cc >72.6 Gy to >1.8-2.0 cc >72.6 Gy to >2.0 cc
Spinal cord* D2% <50 Gy – ≥50 Gy
Brainstem* D2% <52 Gy – ≥52 Gy
Parotid glands**
• Either gland Mean dose <26 Gy – ≥26 Gy
• Either gland ≥50% <30 Gy – ≥30 Gy
• Both glands combined ≥20 cc <20 Gy – ≥20 Gy
Submandibular gland Mean dose <52 Gy – ≥52 Gy
Oral cavity Max dose outside PTV 50 Gy – ≥50 Gy
Larynx Max dose outside PTV 50 Gy – ≥50 Gy
Other^ As low as possible – –
*Mandatory dose limits. **Investigators must meet at least one of three constraints. ^Optic nerves, chiasm, lenses, mandible, globes, brachial plexus, cochleae etc.
Abbreviation: D2% near max dose, ECE extracapsular extension, LN lymph node, max maximum.
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ation of GTV, CTVs and PTVs) were acceptable, 43.5%
graded as minor deviation and 43.5% as major deviation.
Dosimetry
D98% and D95% constraints were used to evaluate
whether sufficient RT dose was prescribed to the re-
spective volumes (Online Additional file 1). Seventeen
(73.9%) sites met both PTV52.8 Gy-Exact dose con-
straints. For the D98% constraint, there were six major de-
viations, and for the D95%, one minor and five major
deviations. Twenty (87.0%) datasets met both PTV59.4
Gy-Exact constraints; three had major violations for both
D98% and D95%. Based on the D98% of the PTV66 Gy-Exact, 21 were acceptable, with one minor and one major
deviation. In terms of the D95%, 22 were acceptable, with
one major violation. 21 (91.3%) DR datasets met both
PTV66 Gy-Exact constraints. There was no statistical cor-
relation between PTV contour evaluation and whether the
site met PTV52.8 Gy-Exact, PTV59.4 Gy-Exact, or PTV66
Gy-Exact constraints (all p ≥ 0.74). Nine median PTV66
Gy-Exact doses exceeded 66 Gy by >2%. Whether the
PTV66 Gy-Exact was evaluated as acceptable, borderline
or unacceptable did not predict whether the median
PTV66 Gy dose exceeded 66 Gy by 2% (p = 0.86). No
plan exceeded a dose of 72.6 Gy to a volume larger than
1.8 cc outside the PTV66 Gy-Exact. In three datasets,
optimization was probably performed on PTVs not
AB
C
Figure 2 Example of a submitted dataset with contours graded
overall as minor deviation, (A) axial, (B) coronal and (C) sagittal
views. Superior border of GTV-pt (orange) and CTVs insufficiently
high. CTV52.8 Gy (magenta) should not extend outside platysma or
into submental, pretracheal or sternocleidomastoid regions. PTVs
should be carved out of normal structures oral cavity and larynx.
Orange: GTV-pt. Magenta: CTV52.8 Gy. Pink: CTV59.4 Gy. Red: CTV66
Gy. Blue: PTV52.8 Gy-Exact*. Green: PTV2Exact*. Purple: PTV3Exact*.




Figure 3 Example of a submitted dataset with contours graded
overall as major deviation, (A) axial, (B) coronal and (C) sagittal
views. GTV-pt not included in its entirety in all CTVs. Contralateral
level IB-IV not included in CTV52.8 Gy, level V not adequately
included, and level IA included erroneously. For normal tissue
contours, medulla (instead of entire brainstem) and spinal cord
(instead of spinal canal) contoured (not shown). Orange: GTV-pt.
Magenta: CTV52.8 Gy. Pink: CTV59.4 Gy. Red: CTV66 Gy. Blue: PTV52.8
Gy-Exact*. Green: PTV2Exact*. Purple: PTV3Exact*. *PTVExacts denote
PTVs collapsed inside the skin by 5 mm.
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non-IMRT plan used for treatment of the low neck was
not submitted rendering the plan not fully evaluable.Organs at risk
Consensus contour evaluations are displayed subdivided
by whether the OAR met dose constraints (Figure 5). If
Figure 4 Volumes (left y-axis) of delineated CTVs of the participating institutes (small symbols) in comparison to the master CTVs
(large symbol and dashed lines). The second symbols on the x-axis indicate mean volumes with standard deviation of the participating institutes
(cross and solid lines) and median volumes of the participating institutes (gray symbols). The right y-axis indicates the mean virtual radius of the
volumes. From the difference of the mean virtual radius of the institute’s volumes to the dashes lines one can estimate the average distance of
the institute’s delineations to the master delineation. (A) CTV66 Gy (circle) (N = 23) and GTV-pt (diamond) (N = 22) Colour of GTV-pt symbols
indicates grade (green = acceptable, yellow = borderline, red = unacceptable). (B) CTV52.8 Gy (N = 23). (C) CTV59.4 Gy (N = 22). (D) PTV66 Gy-Exact
(N = 23). (E) PTV59.4 Gy-Exact (N = 20). (F) PTV52.8 Gy-Exact (N = 18). Colour of centres (A-W) indicates overall grade.
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not be assessed, it was rated as unacceptable. Other struc-
tures not submitted were rated as missing. Sites met dose
constraints for an average of three OARs out of six (range2–5). Recommended dose constraints were: a mean dose
to either parotid <26 Gy (achieved by 7/23 sites); or ≥50%
of either parotid receiving <30 Gy (achieved by 15/23); or













































































































































































Figure 5 Organ at risk contour evaluation and achievement of dose constraints. Spinal cord, brainstem, and parotids were deemed
mandatory for delineation and/or dose reporting and if one of these structures could not be assessed, it was called unacceptable. Remaining
structures which were not submitted were called missing. Abbreviation: cord – spinal cord; submand – right submandibular gland; oral cav – oral cavity.
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the volume of any CTV or PTV and ability to meet par-
otid dose constraints (all p > 0.20), or between parotid
contour acceptability and meeting constraints (p = 0.17).
Mean dose to the right parotid versus PTV volumes are
shown in the online Additional file 1. The dose limit was
met by one third of sites who contoured the (optional)
right submandibular gland, although it was often included
in the low dose PTV so was difficult to optimally spare.
Recommended doses for both the oral cavity and larynx
excluded overlap with PTV-Exacts. There were statistically
significant correlations between contour grades and
whether the site was able to meet respective dose con-
straints for the brainstem, right submandibular gland, oral
cavity, and larynx (all p ≤0.004). Volumes of CTV58.4 Gy,
CTV66 Gy and PTV58.4 Gy correlated significantly
with left parotid D50 (all p ≤ 0.047), and volumes of
CTV58.4 Gy and PTV58.4 Gy correlated significantly with
left parotid mean dose (both p ≤ 0.043). Average doses
were significantly higher for OARs which did not meet
constraints versus those that did (p ≤ 0.04) (Figure 6).
Discussion
Twenty of twenty-three GTVs, 13 CTVs and 10 PTVs
were evaluated as acceptable or borderline, and three
CTVs excluded part of the preoperative extent of tumour.
Seventy-four percent, 87.0% and 91.3% of PTV52.8 Gy-,
PTV59.4 Gy- and PTV66 Gy-Exacts, respectively, met all
dose constraints. Although the overall degree of variation
in target volume delineation was high, and centers’ vol-
umes tended to be larger than the master contours
(Figure 4) with the exception of elective nodal vol-
umes, deviations were smaller in the high risk volumes
(GTV-pt and CTV66 Gy). The mean distance of theGTV-pt contour from the master contour was, with
the exception of one center, below 2.5 mm based on
the mean virtual radius (Figure 4). Dosimetric data can
be considered a proxy for the biologic effects of proto-
col treatment, had it been delivered [23], and since
most locoregional recurrences occur in the high risk
volume, this variation between centers would be ex-
pected to have a low impact on locoregional tumor
control. The main causes of poor compliance with the
guidelines were that the delineation of the nodal levels
and the CTV margins on the GTV-pt were not per-
formed entirely according to protocol.
Similar to the current study, investigators from the
PARSPORT multicenter randomized trial were asked to
delineate volumes as per protocol which were then
compared centrally with a master set [24]. For three
submissions, there were no significant differences be-
tween submitted and reference volumes; there were
small discrepancies in four, attributed to the learning
curve and inter-observer variability. Large differences
from lack of adherence to the trial guidelines were
found in the remaining three representing exclusion of
specific anatomical areas or nodal levels. Planners also
created PTVs based on CTV and OAR volumes pro-
vided [24]. Eight centres achieved the required dose
constraints with the other two within 2%. Cord and
brainstem tolerances were not exceeded in any plan.
The average mean contralateral parotid dose was 25.5 Gy.
All contralateral parotid doses <24 Gy were delivered with
dynamic IMRT using 5 mm width leaves. The authors
concluded that differences in parotid sparing were likely
due to MLC leaf width rather than delivery technique; this
information is not available for datasets in the present
study [24].
Figure 6 Comparative average doses for organs at risk which met or did not meet dose constraints. *p < 0.0001, **p < 0.01, ***p = 0.04. N
denotes number of sites submitting a given structure. Abbreviations: avg – average; submand – submandibular gland.
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to explain the reasons behind large discrepancies in target
volume delineation [25]. Radiation oncologists from 11
centres received a CD containing a CT scan and MRI se-
quences for a 72 year old man with a well-differentiated
T3N0 base of tongue HNSCC. The authors reported in-
creased GTV homogeneity when more precise radiological
imaging was available (contrast, thinner CT slices, multiple
modalities). PTVs were more homogeneously defined, par-
tially compensating for relative inconsistencies in GTV
and CTV contours. The authors concluded that the main
reasons for observed differences were variable interpret-
ation of protocol instructions and ICRU definitions, par-
ticularly the CTV, and a compensation effect of the PTV
where a clinical margin was subconsciously added [25]. In
our study, median volumes of CTV52.8 Gy, CTV59.4 Gy
and CTV66 Gy were on average 7%, 32%, and 24% larger
than the respective master contours, suggesting that local
investigators also tended to incorporate a safety margin.
Nelms et al. examined variation in OAR contours in a
patient with oropharyngeal cancer to quantify inter-
clinician variability as well as changes in IMRT dosim-
etry due strictly to OAR differences [26]. Investigators
were provided with a CT dataset that included a pre-
contoured GTV, three CTVs, and three PTVs. OAR def-
inition was left to the discretion of local investigators;
major variations were seen in resulting OAR sizes and
shapes. The dosimetric impact of variation in OAR con-
tours was estimated by overlying the reference OARs
onto each site’s optimized dose grid. Reported dose dif-
ferences depended on the degree of contour variation
and the plan’s dose gradients with smaller differencesseen with increasing OAR accuracy [26]. We provided
multimodality imaging (preoperative CT and MRI) and
references to OAR atlases to attempt to address this po-
tential source of interobserver variation.
The ability to meet a dose-volume constraint is also
dependent on the proximity of an OAR to a high-dose
PTV or steep dose gradient [18,23,25-27]. The require-
ment to meet a single dose-volume constraint, consid-
ered a limitation in previous IMRT comparison studies
[28], was avoided by provision of up to three constraints
per structure in this trial. This alllows greater flexibility
in how dose objectives can be met [18], although may
increase plan heterogeneity.
A modern protocol should leave freedom in RT tech-
nique but clearly describe target volumes, dose homogen-
eity requirements, dose prescription, relative priorities,
and dose-volume constraints to unambiguously specified
OARs [29]. This study had a few limitations. A clearer dis-
tinction between requirements versus recommendations
for OAR contours may have decreased the number of vio-
lations since absence of a mandatory structure resulted in
an ‘unacceptable’ rating. Although both CT and MRI were
provided for the DR patient, 18 F-FDG PET was not uti-
lized. Preoperative PET images may have helped delinea-
tion of the GTV and therefore increased inter-observer
agreement [30,31]. Regular progress meetings for clini-
cians using the same TPS and hardware for structured
knowledge transfer, as suggested by Clark et al. [24] were
not performed. In evaluating acceptability of target vol-
umes, a reference must be defined. It could be argued
whether our set of master contours was worthy of being
the gold standard, but as per Nelms et al., given any
Fairchild et al. Radiation Oncology  (2014) 9:248 Page 9 of 10reference dataset, variability would still exist [26]. Finally,
inter-centre comparison of OAR doses was complicated
by the fact that each centre created its own contours, mak-
ing it harder to determine the degree to which differences
were influenced by planning technique.
Steps have already been taken to address the last issue
in the form of a two-step DR procedure. First, the DR
case is sent to participating centres for delineation of
volumes, along with a list of requirements for compli-
ance and predefined major deviations. Via an iterative
process, local investigators resubmit volumes for evalu-
ation until no major deviations are identified. Minor de-
viations are also reported to participating centres but
correction is not required. In the second step, the master
contours are sent to centres, based on which a protocol-
compliant treatment plan is generated and centrally
reviewed. This guarantees the same starting conditions
for all centres. Additional means by which improvement
in DR quality could be achieved would depend on deter-
mining specific reasons for non-compliance within each
trial; potential reasons have been recently reviewed [19].
Conclusions
Wide variation in dose planning in the EORTC 22071
dummy run confirms the complexity of development of
IMRT-based multicentre clinical studies for head and
neck cancer, and underscores the need for insistence on
adherence to strict QA procedures for the present time.
Additional file
Additional file 1: Dummy run case. Table S1. Volume and dose
statistics for CTVs and PTVs. Dosimetric indices for CTVs not prespecified
in protocol. Abbreviations: avg – average; N/a – not applicable;
SD – standard deviation. Figure S1. Mean dose to right parotid versus
planning target volumes. (A) PTV52.8 Gy (B) PTV59.4 Gy (C) PTV66 Gy.
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